Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
With the collection of the baseline data from the de novo PD and Health Control subjects complete, PPMI has made Baseline Summary tables available to researchers with access to the database. These pages give researchers a snapshot of what the Baseline Data looks like.
After the announcement that The New York Stem Cell Foundation (NYSCF) Research Institute will partner with PPMI to generate stem cell lines from PPMI participants, The Michael J Fox Foundation for Parkinson’s Research (MJFF) hosted a podcast entitled “Whatever Happened to Stem Cells?”. MJFF Contributing Editor Dave Iverson reported on the new technology NYSCF will use and the current state of stem cell research in Parkinson’s disease.
Qualified researchers may now request access to clinical data and biospecimens from a collection of studies exploring promising areas in Parkinson’s research, including PPMI. The Michael J Fox Foundation for Parkinson’s Research (MJFF) is also offering funding for use and analysis of the available information and materials to progress therapeutic and disease-modifying treatments. In December, MJFF will conduct its final review of this year’s submissions for access to biospecimens or data and for grants of up to $250,000 over two years.
A summary of the Parkinson’s Progression Markers Initiative (PPMI) was recently published in Practical Neurology. The article gives a detailed account of the history and rationale of the study, as well as an overview of the study protocol. The newly added Prodromal and Genetic cohorts are also described in detail, as well as the potential overlap with the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Last week, The New York Stem Cell Foundation (NYSCF) Research Institute announced in a press release that they will partner with PPMI to generate stem cell lines from PPMI participants. The stem cell lines will used to understand the etiology and progression of the disease as compared to the existing and future biomarker data in the PPMI database.